If Section 3(d) is the pharmaceutical patent’s gatekeeper, Section 3(e) is the agrochemical formulator’s. A mixture of two known actives is patentable only if the combination does something more than add up — the proverbial 1 + 1 = 3. In Crystal Crop Protection Ltd. v. Assistant Controller of Patents and Designs [C.A.(COMM.IPD-PAT) 19/2023], the Delhi High Court looked at a herbicide combining halosulfuron-methyl (10–15%) with metribuzin (50–60%), found that the only thing going up was the dose, and held the claim squarely barred by Section 3(e). On the way, it did something procedurally striking: it let the opponent bring fresh prior art at the appeal stage.
The procedural sleeper: new prior art on appeal
Before the merits, the Court dealt with an application by the pre-grant opponent (the Haryana Pesticides Manufacturers’ Association) under Order XLI Rule 27 of the CPC read with the IPD Rules, seeking to place additional prior art on record. Crystal Crop objected that the opponent had every opportunity during the pre-grant opposition and was merely filling lacunae at the appellate stage without showing due diligence. The Court was unmoved: the determinative question, it held, is whether the additional material is necessary to enable the Court to pronounce a satisfactory judgment. The documents — known herbicidal compositions and the functional properties of the actives — were directly relevant, and in they went. Applicants should note the asymmetry: in an appeal from a refusal, the opponent can get a second bite at the prior-art apple.
The synergy question, scrutinised
On the merits, Crystal Crop’s case rested entirely on synergy: the specific combination and concentrations, it argued, delivered enhanced weed control at reduced dosages — a technical advance, not a mere mixture. The trial data, it said, was not just a function of higher dosage per acre, and a person skilled in the art would not expect “enhancement” from reducing the actives; to reason otherwise was hindsight. The Controller and opponent saw it differently: both actives, and their combination, were already in the prior art; the “invention” was the selection of a concentration range; and the data simply reflected more active doing more work.
The Court sided with the Office, and did so with useful clarity. The prior art disclosed combinations of sulfonylurea-class herbicides (halosulfuron-methyl being a member) with metribuzin; varying the proportions fell within the routine experimentation a skilled person would undertake, so there was no technical advance and no inventive step under Section 2(1)(ja). On Section 3(e), the Court held it is not enough to assert that a combination outperforms its components; what must be shown is a synergistic effect — a combined increase in bio-efficacy and stability beyond the sum of the individual effects. The data showed improvement explained by the increased effective quantity of actives, not by any inherent interaction. And then the clincher, now a recurring refrain: “synergistic effect should be clearly brought out in the description by way of comparison at the time of filing of the application itself.” The claim was hit by Section 3(e), and the reasoned refusal was left undisturbed.
Why it matters
This is the orthodox, demanding Indian line on Section 3(e) — the Manual of Patent Office Practice and Procedure requires “functional reciprocity” or a “combinative effect beyond the sum of the individual effects,” and Crystal Crop applies it without blinking. The “at the time of filing” rule is the part that keeps catching applicants: a synergy table assembled after the examiner’s objection lands is treated as support at best, never as the foundation the specification should have laid on day one.
There is a technical lesson hiding in the loss. The right way to demonstrate herbicidal or fungicidal synergy is a constant-dose comparison against a reference expectation — the Colby or Wadley models — so that any greater-than-additive effect is attributable to interaction, not to a heavier loading. Crystal Crop’s dose-escalation data answered the wrong question. The EPO reaches the same destination through its agrochemical leading case, T 939/92 (AgrEvo): a claimed effect must be credible across substantially the whole scope, and an arbitrary range is not inventive. Pair the procedural point (fresh prior art on appeal) with the substantive one (synergy proven on day one or not at all), and this is a quietly tough decision for combination applicants — a reminder that synergy is provable, but only if you design the experiment for it and put it in the spec from the start.
Sources & further reading: Section 3(e), Patents Act; Section 2(1)(ja); Order XLI Rule 27, CPC; Manual of Patent Office Practice and Procedure.
Educational note: This case summary is general information, not legal advice.